Lone Furrow Investments Private Limited, a promoter of medplus health services , has declared that it has not created any encumbrance on the shares held by the company during the Financial Year 2025-26. The disclosure was submitted to the stock exchanges on April 4, 2026, in compliance with Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

The declaration explicitly states that the promoter has not made any encumbrance on the shares of MedPlus Health Services Limited, either directly or indirectly, other than those that were already disclosed during the specified financial year. This confirmation provides assurance to shareholders regarding the status of the promoter's shareholding.

Declaration Details

The communication was addressed to the Audit Committee of MedPlus Health Services Limited and the stock exchanges. It confirmed that the promoter's holding remains free from new charges or encumbrances for the period in question.

The declaration was signed by Gangadi Madhukar Reddy, Director of Lone Furrow Investments Private Limited. The document was submitted to BSE Limited and the National Stock Exchange of India Limited for their records and to inform the investing public.

MedPlus Health Services reported a strong financial performance for the quarter and financial year ended March 31, 2026. The company's revenue for Q4 FY26 stood at ₹18,644m, marking a 23.5% increase compared to the same period in the previous year. Sequentially, revenue grew by 3.2% from the preceding quarter. The full fiscal year 2026 revenue reached ₹68,925m, a 12.3% increase over FY25. The Board of Directors approved the audited standalone and consolidated financial results for the period at a meeting held on May 20, 2026. The extract of these results was published in Financial Express and Nava Telangana on May 22, 2026, pursuant to Regulation 47 of SEBI LODR.

Financial Performance

The company's profitability metrics improved during the period. Net profit for Q4 FY26 was ₹640m, up 24.6% year-on-year. For the full year, net profit surged 46.2% to ₹2,196.1m. EBITDA for the quarter rose to ₹1.898B compared to ₹1.522B in Q4 FY25, with the EBITDA margin improving to 10.2% from 10.1% year-on-year. Operating EBITDA for the quarter stood at ₹1,076m, representing a margin of 5.8%, compared to 5.3% in Q4 FY25. On a full-year basis, operating EBITDA stood at ₹3,658m with a margin of 5.3%.

The following table summarises the key financial metrics for the quarter:

Operational Highlights

MedPlus expanded its store network significantly during the fiscal year. The company added 618 stores on a net basis, bringing the total count to 5,330 stores as of March 31, 2026. In Q4 FY26 alone, the company added 218 stores net, with 295 gross additions and 77 closures. The expansion strategy focused on deeper penetration in existing clusters and growth beyond Tier-One cities, with 384 net additions recorded beyond Tier-One areas during the year.

Segment and Store Metrics

The pharmacy segment remained the primary revenue driver, contributing ₹18,266m in revenue for Q4 FY26. Stores older than 12 months demonstrated strong operational efficiency, reporting a store-level EBITDA margin of 13.1% and an operating ROCE of 80.0% for the quarter. The company's gross margin for the quarter improved to 26.5%, while the full-year gross margin stood at 26.2%, an increase of 180 basis points over FY25.